1Department of Pharmacovigilance and Rational Pharmacotherapy Agency for Medicinal Products and Medical Devices of Croatia 10000 Zagreb, Croatia.
2Centre for Applied Pharmacy, Faculty of Pharmacy and Biochemistry University of Zagreb, 10 000 Zagreb Croatia.
Acta Pharm. 2023 Jun 12;73(2):293-310. doi: 10.2478/acph-2023-0029. Print 2023 Jun 1.
We aimed to identify whether a spontaneous reporting system (SRS) in Croatia could timely identify and confirm signals for COVID-19 vaccines. Post-marketing spontaneous reports of adverse drug reactions (ADRs) following COVID-19 immunisation reported to the Agency for Medicinal Products and Medical Devices of Croatia (HALMED) were extracted and analysed. 6624 cases reporting 30 655 ADRs following COVID-19 immunisation were received from 27 December 2020 to 31st December 2021. Available data in those cases were compared with data available to the EU network at the time when signals were confirmed and minimisation measures were implemented. 5032 cases, reporting 22 524 ADRs, were assessed as non-serious, and 1,592 cases, reporting 8,131 ADRs as serious. The most reported serious ADRs, which were listed in the MedDRA Important medical events terms list, were syncope ( = 58), arrhythmia ( = 48), pulmonary embolism ( = 45), loss of consciousness ( = 43), and deep vein thrombosis ( = 36). The highest reporting rate had Vaxzevria (0.003), followed by Spikevax and Jcovden (0.002), and Comirnaty (0.001). Potential signals were identified, however, they couldn't be timely confirmed solely on cases retrieved by SRS. In order to overcome the limitations of SRS, active surveillance and post-authorisation safety studies of vaccines should be implemented in Croatia.
我们旨在确定克罗地亚的自发报告系统(SRS)是否能够及时识别和确认 COVID-19 疫苗的信号。从 2020 年 12 月 27 日至 2021 年 12 月 31 日,从克罗地亚药品和医疗器械管理局(HALMED)收到了 6624 例报告 COVID-19 免疫后不良药物反应(ADR)的自发报告,共 30655 例。对这些病例中的可用数据与信号得到确认和采取缓解措施时欧盟网络中可用的数据进行了比较。5032 例,报告 22524 例非严重 ADR,1592 例,报告 8131 例严重 ADR。报告最多的严重 ADR 是晕厥(=58)、心律失常(=48)、肺栓塞(=45)、意识丧失(=43)和深静脉血栓形成(=36),这些都是 MedDRA 重要医学事件术语列表中列出的。Vaxzevria(0.003)的报告率最高,其次是 Spikevax 和 Jcovden(0.002),以及 Comirnaty(0.001)。虽然识别到了潜在信号,但仅凭 SRS 检索到的病例无法及时确认。为了克服 SRS 的局限性,应在克罗地亚实施疫苗主动监测和上市后安全性研究。